Stocks of Dyne Therapeutics Inc (NASDAQ:DYN) traded higher last session on Wall Street, down -6.19% to $9.40.
DYN stock price is now -12.63% away from the 50-day moving average and -62.40% away from the 200-day moving average. The market capitalization of the company currently stands at $1.07B.
With the price target of $50, BMO Capital Markets recently initiated with Outperform rating for Dyne Therapeutics Inc (NASDAQ: DYN). On March 07, 2025, Scotiabank recently initiated its ‘Sector Outperform’ rating on the stock quoting a target price of $50, while ‘Robert W. Baird’ rates the stock as ‘Outperform’
In other news, Friedl-Naderer Johanna, Chief Commercial Officer sold 143 shares of the company’s stock on Mar 13 ’25. The stock was sold for $1,733 at an average price of $12.12. Upon completion of the transaction, the Chief Commercial Officer now directly owns 96,057 shares in the company, valued at $0.9 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 11 ’25, SVP, Head of Finance & Admin. Scalzo Richard William sold 1,343 shares of the business’s stock. A total of $15,283 was realized by selling the stock at an average price of $11.38. This leaves the insider owning 122,330 shares of the company worth $1.15 million. A total of 22.80% of the company’s stock is owned by insiders.
During the past 12 months, Dyne Therapeutics Inc has had a low of $6.36 and a high of $47.45. As of last week, the company has a debt-to-equity ratio of 0.04, a current ratio of 15.60, and a quick ratio of 15.60.
